Similar articles for PMID: 22204436

Year	Number of Results
1978	2
1984	1
1991	1
1994	1
1995	1
1997	1
1998	1
1999	2
2000	1
2001	1
2002	4
2003	4
2004	4
2005	6
2006	8
2007	7
2008	11
2009	15
2010	15
2011	30
2012	25
2013	35
2014	51
2015	7
2016	10
2017	7
2018	22
2019	41
2020	38
2021	51
2022	47
2023	15
2024	0

1

Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes.

Yamagishi S, Matsui T. Yamagishi S, et al. Curr Pharm Des. 2011 Dec;17(38):4379-85. doi: 10.2174/138161211798999456. Curr Pharm Des. 2011. PMID: 22204436 Review.

2

Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.

Vergès B, Bonnard C, Renard E. Vergès B, et al. Diabetes Metab. 2011 Dec;37(6):477-88. doi: 10.1016/j.diabet.2011.07.001. Epub 2011 Aug 25. Diabetes Metab. 2011. PMID: 21871831 Review.

3

Incretins: their physiology and application in the treatment of diabetes mellitus.

Tasyurek HM, Altunbas HA, Balci MK, Sanlioglu S. Tasyurek HM, et al. Diabetes Metab Res Rev. 2014 Jul;30(5):354-71. doi: 10.1002/dmrr.2501. Diabetes Metab Res Rev. 2014. PMID: 24989141 Review.

4

Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.

Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ. Nauck MA, et al. Circulation. 2017 Aug 29;136(9):849-870. doi: 10.1161/CIRCULATIONAHA.117.028136. Circulation. 2017. PMID: 28847797 Review.

5

Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.

Nauck M. Nauck M. Diabetes Obes Metab. 2016 Mar;18(3):203-16. doi: 10.1111/dom.12591. Epub 2016 Jan 5. Diabetes Obes Metab. 2016. PMID: 26489970 Free PMC article. Review.

6

The potential for renoprotection with incretin-based drugs.

Tanaka T, Higashijima Y, Wada T, Nangaku M. Tanaka T, et al. Kidney Int. 2014 Oct;86(4):701-11. doi: 10.1038/ki.2014.236. Epub 2014 Jul 9. Kidney Int. 2014. PMID: 25007170 Free article. Review.

7

Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells.

Lee YS, Jun HS. Lee YS, et al. Metabolism. 2014 Jan;63(1):9-19. doi: 10.1016/j.metabol.2013.09.010. Epub 2013 Oct 17. Metabolism. 2014. PMID: 24140094 Review.

8

The entero-insular axis: implications for human metabolism.

Ranganath LR. Ranganath LR. Clin Chem Lab Med. 2008;46(1):43-56. doi: 10.1515/CCLM.2008.008. Clin Chem Lab Med. 2008. PMID: 18020966 Review.

9

Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.

Neumiller JJ. Neumiller JJ. J Am Pharm Assoc (2003). 2009 Sep-Oct;49 Suppl 1:S16-29. doi: 10.1331/JAPhA.2009.09078. J Am Pharm Assoc (2003). 2009. PMID: 19801361 Review.

10

Incretins and Their Endocrine and Metabolic Functions.

Seufert J. Seufert J. Endocr Dev. 2017;32:38-48. doi: 10.1159/000475730. Epub 2017 Aug 15. Endocr Dev. 2017. PMID: 28873383

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

420 results

Results by year